- Home
- VGZ vs BNR Comparison
VGZ vs BNR Comparison
Compare VGZ & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- BNR
- Stock Information
- Founded
- VGZ 1983
- BNR 2014
- Country
- VGZ United States
- BNR China
- Employees
- VGZ N/A
- BNR 786
- Industry
- VGZ
- BNR Medical Specialities
- Sector
- VGZ
- BNR Health Care
- Exchange
- VGZ Nasdaq
- BNR Nasdaq
- Market Cap
- VGZ 71.2M
- BNR 36.6M
- IPO Year
- VGZ N/A
- BNR 2020
- Fundamental
- Price
- VGZ $0.70
- BNR $3.62
- Analyst Decision
- VGZ Strong Buy
- BNR
- Analyst Count
- VGZ 1
- BNR 0
- Target Price
- VGZ $2.75
- BNR N/A
- AVG Volume (30 Days)
- VGZ 401.2K
- BNR 8.2K
- Earning Date
- VGZ 10-23-2024
- BNR 08-22-2024
- Dividend Yield
- VGZ N/A
- BNR N/A
- EPS Growth
- VGZ N/A
- BNR N/A
- EPS
- VGZ 0.09
- BNR N/A
- Revenue
- VGZ N/A
- BNR $70,154,674.00
- Revenue This Year
- VGZ N/A
- BNR $52.90
- Revenue Next Year
- VGZ N/A
- BNR $48.35
- P/E Ratio
- VGZ $7.49
- BNR N/A
- Revenue Growth
- VGZ N/A
- BNR N/A
- 52 Week Low
- VGZ $0.30
- BNR $3.43
- 52 Week High
- VGZ $0.73
- BNR $11.70
- Technical
- Relative Strength Index (RSI)
- VGZ 71.91
- BNR 21.40
- Support Level
- VGZ $0.53
- BNR $3.43
- Resistance Level
- VGZ $0.63
- BNR $4.97
- Average True Range (ATR)
- VGZ 0.04
- BNR 0.34
- MACD
- VGZ 0.01
- BNR -0.17
- Stochastic Oscillator
- VGZ 99.90
- BNR 4.31
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects, which may lead to gold production or value adding strategic transactions. These activities are currently focused principally in Australia.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.